ArticleNature biotechnology2024
Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice.
Article in Nature biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 3 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Bacteriophages as post-harvest biocontrol agents againstFrontiers in nutrition · 2026Pooled it
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2026Pooled it
- Bacteriophages as a Biocontrol Strategy to Prevent the Contamination of Meat Products with Escherichia coli - a Meta-Analysis.Polish journal of microbiology · 2025Pooled it
- Dietary and nutritional strategies for reducing disease risk associated with antibiotic-induced dysbiosis.Gut microbes · 2026Review
- Microbiome-based therapeutics forGut microbes · 2026Review
- The global patent landscape of CRISPR-Cas applications in medicine.Nature biotechnology · 2026Article
- Gut microbiome dynamics in acute infectious diarrhea: A conceptual framework from acute dysbiosis toward precision restoration (Review).Experimental and therapeutic medicine · 2026Review
- A bacteriophage split DNA polymerase incorporates a sliding clamp-derived processivity subunit.bioRxiv : the preprint server for biology · 2026Article
- One Plasmid Is All You Need: Genome Editing in Escherichia coli Using Endogenous TnpB and Endogenous Recombination System.Biotechnology and bioengineering · 2026Article
- Non-Traditional Antibacterial Agents Relevant to the WHO 2024 Priority Pathogens: A Structured Update of the Clinical Pipeline.Antibiotics (Basel, Switzerland) · 2026Review
- Approaching the post-antibiotic era: phage therapy current practices and future horizons.mBio · 2026Review
- Recent Advances in CRISPR/Cas Technologies for Biological Discovery, Therapeutics, and Diagnostics.Biomolecules · 2026Review
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
- CRISPR-cas systems in pharmacology: functional pharmacogenomics, drug screening, resistance, and therapeutic translation.Functional & integrative genomics · 2026Review
- Phage therapy: from basic biology to clinical application.Nature reviews. Microbiology · 2026Review
- Review
- Addressing antimicrobial resistance: Current challenges, emerging strategies, and an AI-powered, community-driven approach.PNAS nexus · 2026Review
- Bacterial immune systems.Antonie van Leeuwenhoek · 2026Review
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Profiling the gut resistome to unlock antimicrobial resistance biology and inform clinical risk.Nature communications · 2026Review
115 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
36 authors at 3 institutions in 2 countries.
Funding
Abstract
Antibiotic treatments have detrimental effects on the microbiome and lead to antibiotic resistance. To develop a phage therapy against a diverse range of clinically relevant Escherichia coli, we screened a library of 162 wild-type (WT) phages, identifying eight phages with broad coverage of E. coli, complementary binding to bacterial surface receptors, and the capability to stably carry inserted cargo. Selected phages were engineered with tail fibers and CRISPR-Cas machinery to specifically target E. coli. We show that engineered phages target bacteria in biofilms, reduce the emergence of phage-tolerant E. coli and out-compete their ancestral WT phages in coculture experiments. A combination of the four most complementary bacteriophages, called SNIPR001, is well tolerated in both mouse models and minipigs and reduces E. coli load in the mouse gut better than its constituent components separately. SNIPR001 is in clinical development to selectively kill E. coli, which may cause fatal infections in hematological cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.